Global Immuno-oncology Drugs Market Size By Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies), By Application (Hospitals, Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Immuno-oncology Drugs Market was valued at USD 105.3 billion in 2023 and is projected to reach USD 271.6 billion by 2031, growing at a CAGR of 12.6% during the forecast period from 2023 to 2031. This remarkable growth is driven by the increasing prevalence of cancer, rising demand for targeted therapies, and ongoing advancements in immunotherapy research. Immuno-oncology drugs leverage the body’s immune system to fight cancer, offering a promising alternative to traditional treatments such as chemotherapy and radiation. With an increasing number of FDA approvals, growing patient awareness, and expanding applications across multiple cancer types, the market is expected to witness substantial expansion globally.

Drivers:

1. Rising Global Cancer Burden:

The increasing incidence of various cancers, including lung, melanoma, and breast cancer, is fueling the demand for effective treatments. Immuno-oncology drugs provide improved survival rates and fewer side effects, making them a preferred option.

2. Technological Advancements and FDA Approvals:

The market is benefitting from continual innovations in drug development, including checkpoint inhibitors, CAR-T cell therapies, and bispecific antibodies. Accelerated FDA approvals of novel therapies are also expediting patient access.

3. Expanding Indications and Combinational Therapies:

The use of immuno-oncology drugs is expanding to earlier lines of therapy and more cancer types. Additionally, combination therapies are gaining traction for their synergistic effects, improving overall efficacy.

Restraints:

1. High Treatment Costs:

Immuno-oncology therapies often come with high price tags, making them less accessible in low- and middle-income countries and placing financial strain on healthcare systems and patients.

2. Variable Patient Response:

Not all patients respond equally to immuno-oncology drugs, and biomarkers to predict treatment success are still in development, limiting the precision of patient selection.

Opportunity:

1. Emergence of Personalized Medicine:

Advances in genomics and proteomics are paving the way for personalized immunotherapies tailored to individual patient profiles, opening new revenue streams for pharmaceutical companies.

2. Market Expansion in Emerging Economies:

Rising healthcare expenditures, expanding oncology infrastructure, and improved access to advanced therapies in countries like India, China, and Brazil are creating lucrative growth opportunities.

Market by Drug Type Insights:

Checkpoint inhibitors dominated the market in 2023, driven by strong sales of PD-1/PD-L1 inhibitors such as pembrolizumab and nivolumab. These agents have shown robust efficacy across multiple cancer types and continue to gain new indications. CAR-T cell therapy is the fastest-growing segment, owing to its success in treating hematologic malignancies and the ongoing development of allogeneic CAR-T solutions.

Market by End-use Insights:

The hospital segment held the largest market share in 2023, attributed to the complexity of immuno-oncology treatment administration, which often requires inpatient care, monitoring, and specialized infrastructure. Cancer research institutes are also expected to witness growth due to increasing clinical trials and academic collaborations.

Market by Regional Insights:

North America led the global market in 2023, supported by high healthcare spending, robust R&D activities, and early adoption of innovative therapies. However, the Asia-Pacific region is projected to exhibit the highest CAGR, driven by increasing cancer prevalence, improving healthcare access, and growing investments in biotech innovation.

Competitive Scenario:

Key players in the global immuno-oncology drugs market include Bristol Myers Squibb, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Pfizer Inc., Johnson & Johnson, Amgen Inc., Gilead Sciences, and BeiGene Ltd. These companies are investing heavily in R&D, strategic partnerships, and expanding their immuno-oncology pipelines. For example:

In 2024, Merck received regulatory approval for its new PD-1/CTLA-4 bispecific antibody targeting melanoma and lung cancer.

In 2023, AstraZeneca expanded its oncology pipeline through a strategic partnership with a biotech startup specializing in neoantigen vaccines.

In 2025, Bristol Myers Squibb launched a next-generation CAR-T therapy for relapsed multiple myeloma.

Scope of Work – Global Immuno-oncology Drugs Market

Key Market Developments:

Jan 2024: Bristol Myers Squibb received FDA approval for its novel CD19-targeted CAR-T cell therapy for aggressive B-cell lymphoma.

Mar 2023: Roche announced positive Phase III trial results for its novel checkpoint inhibitor combination in non-small cell lung cancer.

Nov 2023: Gilead Sciences entered into a collaboration agreement with a biotechnology firm to co-develop T-cell receptor therapies.

May 2025: Novartis launched its AI-driven platform for immuno-oncology drug discovery, aiming to accelerate time-to-market.

FAQs:

1) What is the current market size of the Global Immuno-oncology Drugs Market?

The market was valued at USD 105.3 billion in 2023.

2) What is the major growth driver of the Global Immuno-oncology Drugs Market?

Key growth drivers include rising cancer incidence and advancements in targeted immunotherapies.

3) Which is the largest region during the forecast period in the Global Immuno-oncology Drugs Market?

North America is the largest regional market, though Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Immuno-oncology Drugs Market?

Checkpoint inhibitors led the market in 2023.

5) Who are the key market players in the Global Immuno-oncology Drugs Market?

Leading companies include Merck & Co., Bristol Myers Squibb, Roche, AstraZeneca, Pfizer, and Novartis.